Compare Adaptive Biotechnologies Corp (ADPT) vs QUALCOMM, Inc. (QCOM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs QUALCOMM, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while QUALCOMM, Inc. trades at $187.2 (market cap $192.85B). The key difference: QUALCOMM, Inc. is far larger — about 57.9× Adaptive Biotechnologies Corp's market cap, and QUALCOMM, Inc. pays a 2.01% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | QCOM | |
|---|---|---|
Market Cap | $3.33B | $192.85B |
Sector | Health | Technology |
52-Week High | $22.37 | $251.10 |
52-Week Low | $10.24 | $124.07 |
Enterprise Value | $3.19B | $198.32B |
Dividend Yield | — | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Qualcomm (QCOM) trades at $186.52, up 0.02% on the day, with a bearish technical signal and key support at $180. The company reported strong recent earnings beats, with Q1 2026 EPS of $2.65 surpassing the $2.56 estimate. Revenue for 2025 reached $44.28B, though net income margin declined to 12.51%. Analyst consensus is a Buy with a $221.21 price target, while recent news highlights competitive pressures from Nvidia's entry into the PC chip market.
The outlook for QCOM is mixed; diversification into AI and automotive offers growth, but smartphone market softness and margin pressures pose near-term risks. Valuation metrics like a P/E of 19.67 and ROE of 29.27% suggest solid fundamentals, yet investors face volatility from intense semiconductor competition and cyclical demand swings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →
